TrialFinder  /  Landscape Report AUTISM  ·  2026-10-26 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-10-26
VERSION  v1
SAMPLE  100 of 9087 studies

autism

The autism clinical trial landscape includes 9087 actively recruiting trials. Semantic expansion identified 8712 additional trials beyond exact-match search, representing a 2323.2% discovery lift across related conditions and therapeutic approaches.

Recruiting
9087
active trials
Expansion Lift
+2323.2%
8712 additional trials
Top Sponsor
Sun Yat-sen University
2 trials
Dominant Phase
NA
42 of 108 sampled
Pipeline Overview
Phase Distribution
NA
42
Early I
2
Phase 1
10
Phase 2
17
Phase 3
5
Phase 4
5
Other
27
Therapeutic Modalities
DRUG
55
BEHAVIORAL
34
OTHER
28
PROCEDURE
20
DEVICE
11
DIAGNOSTIC_TEST
7
COMBINATION_PRODUCT
7
BIOLOGICAL
5
Recruiting vs. Completed (2yr)
Recruiting
9087
Completed
4709
Competitive Landscape
Sponsor Classification
84%
11%
5%
OTHER (16)
FED (2)
OTHER_GOV (1)
Top Sponsors
SponsorTrialsClass
Sun Yat-sen University2OTHER
VA Office of Research and Development2FED
The University of Texas Health Science Center, Houston2OTHER
Ruijin Hospital2OTHER
Henan Cancer Hospital1OTHER_GOV
Second Affiliated Hospital, Zhejiang University, School of Medicine1OTHER
Chulalongkorn University1OTHER
University Hospital, Lille1OTHER
Ardahan University1OTHER
Mahidol University1OTHER
Lishu Gao1OTHER
Centre Hospitalier Universitaire de Saint Etienne1OTHER
Istituto Giannina Gaslini1OTHER
Fujian Medical University1OTHER
Case Comprehensive Cancer Center1OTHER
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
Texas10Houston
Massachusetts7Boston
California6Los Angeles
Connecticut6New Haven
Tennessee5Nashville
Pennsylvania4Pittsburgh
Ohio3Cleveland
New York3New York
Maryland2Baltimore
Florida2Miami
North Carolina2Salisbury
Arizona2Scottsdale
Michigan2Grand Rapids
South Carolina1Charleston
Minnesota1Rochester
Alabama1Birmingham
Colorado1Denver
Louisiana1New Orleans
Iowa1Iowa City
Oregon1Portand
Expansion Intelligence
+2323.2%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
3
Exact
1
Parent
3
Related
5
Comorbid
6
Therapeutic
Top Expansion Terms
  • neurodevelopmental disorder Parent
  • Asperger syndrome Related
  • pervasive developmental disorder Related
  • social communication disorder Related
  • anxiety Comorbid
  • ADHD Comorbid
  • epilepsy Comorbid
  • sleep disorder Comorbid
  • gastrointestinal disorder Comorbid
  • oxytocin autism Therapeutic

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for autism
high
Standard searches miss 2323% of relevant trials for autism — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
8712 additional trials found via expansion vs 375 exact matches
high
Phase 2 volume (17) significantly exceeds Phase 3 (5), indicating a pipeline bottleneck — most candidates are 2-4 years from potential approval.
Phase 2/Phase 3 ratio: 3.4x
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for autism and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors
Henan Cancer Hospital n=200 Department of Bone and Soft Tissue ,Henan Cancer Hospital Zhengzhou, Henan
Intervention OTHER: Hospital Anxiety and Depression Scale — The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
Contact Wang Jiaqiang, Dr · 13592413731 · wjqwtj@126.com
NCT05481619 PHASE4
Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine n=30 Second Affiliated Hospital Zhejiang University School of Medicine Zhengzhou, Hangzhou
Intervention DRUG: Vedolizumab — Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter. Discontin...
Eligibility Ages 18 Years
Contact Qiao Yu, phd · 0086-13456820567 · yuqiao@zju.edu.cn
NCT07670611 PHASE4
Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D Deficiency
Chulalongkorn University n=54 King Chulalongkorn Memorial Hospital Bangkok
Intervention DRUG: Vitamin D2 — Vitamin D2 40,000 IU/week weekly
Eligibility Ages 18 Years
Contact THANAPORN NiLYAEM · 66852811244 · namobnamob@docchula.com
NCT06451211 PHASE2
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Sun Yat-sen University n=53 Sun Yat-sen University Cancer Center Guangzhou, Guangdong
Intervention DRUG: Tislelizumab — Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants
Eligibility Ages 18 Years – 75 Years
Contact Haibo Qiu, MD, Ph.D · 020-87343910 · qiuhb@sysucc.org.cn
Perinatal Covid-19 Infection, NO Pathway, and Minipuberty
University Hospital, Lille n=180 Hop Jeanne de Flandre Chu Lille Lille
Intervention OTHER: Inhaled NO — Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
Eligibility Ages 3 Months
Contact Laurent STORME, MD,PhD · 0320445962 · laurent.storme@chru-lille.fr
The Effect of Lavender Inhalation on Anxiety, Sleep, and Blood Pressure
Ardahan University n=50 Ardahan State Hospital Ardahan, Ardahan
Intervention OTHER: Lavender — Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardi...
Contact Derya ŞİMŞEKLİ, PhD · +905545965789 · deryasimsekli@ardahan.edu.tr
Laser vs Electrohydraulic Lithotripsy for Difficult CBD Stones
Mahidol University n=60 Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok, Bangkok
Intervention DEVICE: Laser Lithotripsy — Laser Lithotripsy
Eligibility Ages 18 Years
Contact Ronnakorn Kongsakon, MD · +66655979522 · ronnagorn@gmail.com
Electroacupuncture for Generalized Anxiety Disorder: Clinical Efficacy and Neuroimaging Mechanisms
Lishu Gao n=123 Affiliated Hangzhou First People's Hospital Hangzhou, Zhejiang
Intervention PROCEDURE: Electroacupuncture (EA) — Electroacupuncture (EA) is performed at acupoints including GV20 (Baihui), EX-HN1 (Sishencong), GV29 (Shenting), EX-HN16...
Eligibility Ages 18 Years – 60 Years
Contact Lishu Gao · +86 13858015836 · rodelo@sina.com
Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity
Centre Hospitalier Universitaire de Saint Etienne n=120 Hospices Civils de Lyon Bron
Intervention OTHER: Preparation of forearm molds with SILFLO® silicone — Preparation of forearm molds with SILFLO® silicone (MONADERM, Monaco), CE-marked and already used routinely in dermocosm...
Eligibility Ages 12 Years
Contact Jean Luc PERROT, PHD · (0)4 77 82 83 33 · j.luc.perrot@chu-st-etienne.fr
NCT07809867 PHASE4
Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis
Istituto Giannina Gaslini n=50 IRCCS Istituto Giannina Gaslini Genova
Intervention DRUG: Elexacaftor, Tezacaftor, Ivacaftor — Cystic Fibrosis Transmembrane Regulator (CFTR) modulator therapy
Eligibility Ages 6 Years
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
Fujian Medical University n=194 Department of Gastric Surgery, Fujian Medical University Union Hospital Fuzhou, Fujian
Eligibility Ages 18 Years – 75 Years
Contact Ping Li, MD,PhD · +8613365918502 · Pingli811002@163.com
NCT07117032 PHASE1
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain
Case Comprehensive Cancer Center n=5 University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio
Intervention OTHER: Simulation-free workflow — Pre-existing diagnostic images (CTs, PET/CTs, or MRIs) will be imported into the online treatment planning system called...
Eligibility Ages 18 Years
Contact Lauren Henke, MD, MSCI · (218) 234 -6429 · lauren.henke@uhhospitals.org
Enhancing Generalization of Virtual Reality Exposure for Public Speaking Anxiety
Philipps University Marburg n=48 Department of Psychology, Philipps-University of Marburg Marburg, Hesse
Intervention BEHAVIORAL: VR Exposure — 6 VR speech exposure trials (3 min each; topic: "something you are proud of")
Eligibility Ages 18 Years – 70 Years
Contact Christoph Benke, Ph.D. · +49 6421 28-24091 · christoph.benke@uni-marburg.de
NCT07418593 PHASE4
Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis
Anna Evans Phillips n=80 Johns Hopkins Medicine Baltimore, Maryland
Intervention DRUG: Pancreatic Enzyme Replacement Therapy — 12 participants who are PERT responders in the MBT will be randomized to receive 8 weeks of PERT (144,000 lipase units d...
Eligibility Ages 18 Years
Contact Anna E Phillips, MD MS · 412-864-7096 · Evansac3@upmc.edu
NCT06843551 PHASE2
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Benjamin Spieler n=20 University of Miami Miami, Florida
Intervention RADIATION: Stereotactic Body Radiation Therapy — The radiation therapy (RT) prescription biologically effective dose (BED10) goal for tumor (α/β=10) aims to achieve at l...
Eligibility Ages 18 Years
Contact Benjamin Spieler, MD · 305-243-4229 · bxs737@med.miami.edu
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Zhongda Hospital n=300 Zhongda Hospital Nanjing, Jiangsu
Eligibility Ages 18 Years – 80 Years
Contact Gao-Jun Teng, M.D · +86-02583272121 · gjteng@vip.sina.com
Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation
IRCCS Azienda Ospedaliero-Universitaria di Bologna n=100 IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna
Intervention DIAGNOSTIC_TEST: Immunohistochemistry and in situ hybridisation analysis — immunohistochemistry and in situ hybridisation analysis for several markers, including p53, beta-Catenin and albumin, bu...
Eligibility Ages 18 Years
Contact Francecso Vasuri, MD · 0512143761 · francesco.vasuri2@unibo.it
NCT04932577 PHASE2, PHASE3
Faecal Microbiota Transplantation for Liver Cirrhosis
University of Aarhus n=220 Department of Hepatology and Gastroenterology, Aarhus University Hospital Aarhus
Intervention BIOLOGICAL: Faecal microbiota transplantation — All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
Eligibility Ages 18 Years – 75 Years
Contact Karen Louise Thomsen, PhD · +4526949260 · karethom@rm.dk
NCT06213857 PHASE2
Beneficial Effect of Silymarin in Ulcerative Colitis
Tanta University n=44 Mabarra Hospital Asyut
Intervention DIETARY_SUPPLEMENT: Silymarin — Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a ...
Eligibility Ages 18 Years – 65 Years
Contact Ahmad A Ahmad Eltayeb, Cl.Ph · +201140399467 · PG_165473@pharm.tanta.edu.eg
AI-Assisted Chemotherapy Side Effect Management
Incheon St.Mary's Hospital n=174 Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea Incheon
Intervention BEHAVIORAL: LLM-assisted chemotherapy side effect management — Healthcare providers collect patient symptoms during clinic visits, anonymize the information, and input it into the LLM...
Eligibility Ages 18 Years
Contact Young-Joon Kang · +82322805179 · yjkang.md@gmail.com